Real-World Treatment Outcomes Associated With Early Versus Delayed Vedolizumab Initiation in Patients With Ulcerative
Noa Krugliak Cleveland1, Ninfa Candela2, John A Carter3
1University of Chicago Medicine, Inflammatory Bowel Disease Center, Chicago, IL, USA.
Crohn'S & Colitis 360
|November 6, 2024
Summary
Early vedolizumab treatment for ulcerative colitis (UC) patients led to better response rates at two months and similar healthcare costs compared to delayed treatment. This suggests initiating biologic therapy sooner may improve outcomes for UC management.
Area of Science:
- Gastroenterology
- Clinical Pharmacy
- Health Economics
Background:
- Ulcerative colitis (UC) patients often receive targeted therapies after conventional treatments and disease complications arise.
- Early biologic treatment post-diagnosis may enhance treatment response and prevent complications compared to delayed initiation.
Purpose of the Study:
- To evaluate the impact of early versus delayed vedolizumab treatment on response rates and healthcare costs in ulcerative colitis patients.
Main Methods:
- A retrospective study analyzed IBM MarketScan data (2016-2019) for adult UC patients.
- Patients were categorized into Early or Delayed Vedolizumab groups based on timing of treatment initiation relative to diagnosis and conventional therapies.
- Treatment response was assessed at 2, 6, and 12 months using logistic regression.
Main Results:
- Delayed vedolizumab was associated with significantly higher odds of nonresponse at 2 months (OR, 2.509).
- No significant difference in nonresponse odds was observed at 6 or 12 months.
- Mean 12-month healthcare costs were comparable between Early ($6492) and Delayed ($5897) vedolizumab groups.
Conclusions:
- Early vedolizumab initiation in UC patients was linked to reduced nonresponse at 2 months.
- Healthcare costs remained similar regardless of vedolizumab treatment timing over 12 months.
Related Concept Videos
01:29Drugs for Treatment of Ulcerative Colitis in IBD
124
Ulcerative colitis is a chronic inflammatory condition primarily affecting the colon and rectum. The primary drugs used in the treatment of ulcerative colitis are aminosalicylates. They exhibit anti-inflammatory and immunosuppressive properties. They modulate inflammatory mediators and inhibit the activity of nuclear factor κB (NF-κB). Aminosalicylates also reduce inflammation by inhibiting prostaglandin and leukotriene production and decreasing neutrophil chemotaxis and superoxide...
124
01:29Inflammatory Bowel Disease IV: Pharmacological Management
116
Upon diagnosis, managing Inflammatory Bowel Disease (IBD) involves addressing several crucial aspects. The primary goals include resting the bowel, correcting malnutrition, and providing symptomatic relief. Resting the bowel may consist of medications to reduce inflammation and promote healing. Correcting malnutrition is essential, often requiring dietary adjustments and nutritional supplements. Symptomatic relief aims to ease pain, diarrhea, and other discomforts in IBD.
Pharmacologic...
Pharmacologic...
116
01:17Drugs for Treatment of Diarrhea-Predominant IBS
149
Diarrhea-predominant irritable bowel syndrome (IBS-D) is a subtype of IBS characterized primarily by frequent, loose, or watery stools, abdominal pain, and abdominal discomfort. Therapeutic approaches to managing IBS-D include dietary changes, stress management techniques, and pharmaceutical interventions.
Two specific drugs used in the treatment are alosetron (Lotronex) and eluxadoline (Viberzi). Alosetron, a 5-HT3 antagonist, works by slowing the movement of stools in the gut, reducing bowel...
Two specific drugs used in the treatment are alosetron (Lotronex) and eluxadoline (Viberzi). Alosetron, a 5-HT3 antagonist, works by slowing the movement of stools in the gut, reducing bowel...
149
01:21Drugs for Treatment of Crohn's Disease in IBD Using Glucocorticoids
97
Glucocorticoids, a class of anti-inflammatory drugs, are pivotal in treating moderate to severe Crohn's disease by inducing remission. They exhibit their anti-inflammatory action by inhibiting the production of inflammatory cytokines such as tumor necrosis factor (TNF)-α, interleukin (IL)-1, and chemokines like IL-8. In addition, they reduce the expression of inflammatory cell adhesion molecules and inhibit gene transcription of nitric oxide synthase, phospholipase A2, cyclooxygenase-2...
97
01:21Inflammatory Bowel Disease V: Surgical Management
123
Surgical interventions for inflammatory bowel disease (IBD), which includes ulcerative colitis and Crohn's disease, are essential in managing symptoms and addressing complications. The selection of surgical procedures is contingent upon the specific conditions and complications that stem from these illnesses.
Here are some common surgical interventions for IBD:
Here are some common surgical interventions for IBD:
123
01:26Peptic Ulcer Disease IV: Management
74
Medical treatment strategies for peptic ulcers encompass various methods. The primary goal of treatment is to diminish gastric acidity and strengthen mucosal defense mechanisms.
The therapeutic approach involves ensuring adequate rest, implementing drug therapy, promoting smoking cessation, making dietary modifications, and emphasizing long-term follow-up care.
Pharmacological management
The prevailing therapy for peptic ulcers involves a combination of managing the patient's current...
The therapeutic approach involves ensuring adequate rest, implementing drug therapy, promoting smoking cessation, making dietary modifications, and emphasizing long-term follow-up care.
Pharmacological management
The prevailing therapy for peptic ulcers involves a combination of managing the patient's current...
74